Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 15449762.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.